How to check a compounding pharmacy: confirm it holds an active license with your state board of pharmacy, find out whether it’s a 503A pharmacy or a 503B outsourcing facility, look up any 503B facility on FDA’s registered list, search FDA’s warning letters, and ask whether it’s PCAB-accredited. FDA’s own advice is simple: if a pharmacy isn’t listed with your state’s board, don’t use it.[1] Remember that even a well-run pharmacy makes drugs that aren’t FDA-approved.[6]
This guide explains each check. We don’t name or recommend pharmacies; the goal is to help you verify one yourself. For the rules behind compounding, start with our 503A vs 503B compounding guide and the FDA & Regulation hub.
Step 1: Verify the state pharmacy license
Every pharmacy that dispenses to you needs a license from the state board of pharmacy. FDA’s BeSafeRx tool links to each state’s license search. Select your state, search the pharmacy’s name, and confirm that it’s licensed, that it requires a prescription, that it lists a US address and phone number, and that a licensed pharmacist is available to answer questions.[1]
Check the license status and any public disciplinary actions. If the pharmacy ships from another state, confirm it’s licensed in your state too.
Step 2: Find out whether it’s 503A or 503B
| 503A compounding pharmacy | 503B outsourcing facility | |
|---|---|---|
| Licensed or registered by | State board of pharmacy | Registers with FDA (and is usually state-licensed) |
| Prescription | Needed for an identified patient[3] | Can make batches for office use[4] |
| Manufacturing standard | USP compounding chapters, enforced by states | Federal current good manufacturing practice (cGMP)[4] |
| FDA inspection | Possible, mainly state oversight | Routine, risk-based FDA inspections[4] |
| FDA-approved product? | No[6] | No[6] |
Most peptides dispensed for an individual patient come from 503A pharmacies. Clinics that don’t make their own products must get them from a licensed pharmacy or a registered 503B facility, according to 2026 medical board guidance.[9]
Step 3: Check FDA’s outsourcing facility list (503B)
FDA publishes a list of registered outsourcing facilities, updated weekly. For each facility it shows the initial and latest registration, the date of the last inspection, whether FDA issued a Form 483 (a list of inspection observations), whether there was a recall, and the action that followed, such as a warning letter.[2]
Read the caveats on that page: registration isn’t an endorsement, a Form 483 isn’t a final finding of a violation, “not yet inspected” says nothing about compliance, and state board actions aren’t included.[2] A facility that doesn’t re-register by year-end drops off the list on January 1.[2]
Step 4: Search FDA warning letters
FDA posts warning letters on its website, searchable by company name. Letters to compounders can cite problems such as sterility failures, unlawful ingredients or misleading marketing. Our guide to FDA warning letters about peptides explains how to read them and what recent letters found, and the FDA peptide compounding crackdown covers enforcement trends.
Step 5: Check accreditation
The Pharmacy Compounding Accreditation Board (PCAB) program is run by the Accreditation Commission for Health Care (ACHC). Its non-sterile standard references USP chapter 795, its sterile standard references USP chapter 797, and an add-on covers hazardous drug handling under USP chapter 800. Revised standards took effect June 1, 2024.[5] ACHC’s website has a directory of accredited organizations.[5]
Accreditation is voluntary. Its absence isn’t proof of poor quality, and its presence doesn’t make a compounded drug FDA-approved. It’s one more signal that an outside body has reviewed the pharmacy’s processes.
Step 6: Check that the ingredient is lawful
A licensed, accredited pharmacy can still compound a substance it shouldn’t. Under section 503A, bulk ingredients must have a USP monograph, be part of an FDA-approved drug, or appear on FDA’s 503A bulks list.[3] While FDA reviews nominations, its interim policy sorts substances into categories, and those in the “significant safety risk” category get no enforcement leeway.[10][7]
FDA has also warned that some compounders use salt forms such as semaglutide sodium and semaglutide acetate, which differ from the approved active ingredient, and that it knows of no lawful basis for compounding with them.[8] Ask the pharmacy exactly which ingredient form it uses. See our compounded semaglutide vs Ozempic and compounded GLP-1 additives guides for GLP-1 specifics, and peptide quality standards for testing.
Questions to ask the pharmacy
- Are you licensed in my state? What’s your license number?
- Are you a 503A pharmacy or a 503B outsourcing facility?
- Where does your bulk ingredient come from, and is it the same form as in the approved drug?
- Do you test finished sterile products for sterility and endotoxin?
- What beyond-use date applies, and how should I store it?
- Can I speak with a pharmacist about side effects?
Red flags
- Sells without a prescription, or “prescriptions” generated from a quick online form.
- Products labeled “research use only” or “not for human consumption”; see research use only peptides.
- Offers peptides FDA lists as safety risks for compounding.[7]
- No pharmacist available, no physical address, or no license in your state.[1]
- Vials that arrive warm when they should be cold. FDA advises against using an injectable GLP-1 that arrives warm or without enough refrigeration.[8]
Checklist: checking a compounding pharmacy
- Active license with my state board of pharmacy, with no unresolved discipline.
- I know whether it’s 503A or 503B.
- 503B facility found on FDA’s registered list; inspection history reviewed.
- FDA warning letters searched by name.
- Accreditation status confirmed with ACHC, if claimed.
- Ingredient and its form are lawful to compound.
- A pharmacist answered my questions.
The bottom line
Checking a compounding pharmacy means searching a few public databases and asking some direct questions. A license and clean inspection record lower the risk of a bad batch, but they don’t turn a compounded peptide into an approved drug or prove that it works. For the clinical side, see how to choose a peptide clinic.
